Simple Summary Colorectal cancer (CRC) is the second-leading cause of cancer-related
deaths in the United States, with a 14% five-year survival rate when metastasized. Current …

Anti-EGFR plus chemotherapy is the standard first-line treatment for most patients with MSS,
RAS-WT, left-sided mCRC. Whether this combination is the best treatment for these patients …

Overexpression of the EGFR ligands amphiregulin (AREG)/epiregulin (EREG) may be a
surrogate of EGFR dependency regardless of sidedness in metastatic colorectal cancer …

Exosomes are secreted vesicles made intracellularly in the endosomal system. We have
previously shown that exosomes are not only made in late endosomes, but also in recycling …

As colorectal cancer (CRC) remains a leading cause of cancer-related death, identifying
therapeutic targets and approaches is essential to improve patient outcomes. The EGFR …

Purpose The EGFR ligand, epiregulin (EREG), is highly expressed in colorectal cancers
(CRCs) and a biomarker for predicting benefit in RAS wildtype patients receiving EGFR …

Epidermal growth factor receptor (EGFR) and its activated downstream signalling pathways
play a crucial role in colorectal cancer development and progression. After four decades of …

Abstract Background The FOxTROT trial has reported advantages of neoadjuvant
chemotherapy (NAC) in locally advanced colon cancer (LACC). Here we present results of …

Exosomes are secreted vesicles made intracellularly in the endosomal system. We have
previously shown that exosomes are not only made in late endosomes, but also in recycling …

The ErbB/HER family has an essential role in tumor progression, proliferation, invasion,
metastasis, and migration. ErbB/HER-targeted therapeutic agents have emerged as effective …